Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Cash from Financing Activities (2017 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Cash from Financing Activities for 9 consecutive years, with -$2.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 107.69% to -$2.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $218.0 million, a 13.97% increase, with the full-year FY2025 number at $218.0 million, up 13.97% from a year prior.
  • Cash from Financing Activities was -$2.9 million for Q4 2025 at Rhythm Pharmaceuticals, down from $189.3 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $189.3 million in Q3 2025 to a low of -$2.9 million in Q4 2025.
  • A 5-year average of $43.2 million and a median of $3.4 million in 2024 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: surged 38293.22% in 2022, then plummeted 133.33% in 2023.
  • Rhythm Pharmaceuticals' Cash from Financing Activities stood at $100000.0 in 2021, then skyrocketed by 17265.0% to $17.4 million in 2022, then crashed by 86.05% to $2.4 million in 2023, then soared by 1481.84% to $38.3 million in 2024, then plummeted by 107.69% to -$2.9 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Cash from Financing Activities are -$2.9 million (Q4 2025), $189.3 million (Q3 2025), and -$889000.0 (Q2 2025).